How does trastuzumab emtansine's patent expiry affect drug prices?

When does the Kadcyla patent run out?
The main patent that covers trastuzumab emtansine’s conjugation technology expires in 2028, while a secondary patent protecting the manufacturing process ends in 2029. Data exclusivity, however, will extend the period before any generic or biosimilar can be approved until 2033. [1]

Will the price drop after the patents expire?
Once the patents lapse and exclusivity ends, the market opens to competitors, which usually results in price reductions. Prices for Kadcyla currently hover around $14,000 per infusion; after competition, prices could fall to 20‑50 % of the current level, depending on how aggressively new entrants price their products.

Which companies might launch a cheaper version?
Large specialty biologics firms and emerging biosimilar manufacturers often target high‑cost antibody‑drug conjugates once patents clear. Potential challengers include companies that have already developed trastuzumab‑based biosimilars, as they can adapt their platforms to the emtansine conjugate.

Does data exclusivity keep prices high for a while?
Yes. Even after the patents expire, the FDA’s data exclusivity period protects Kadcyla’s clinical data until 2033, preventing competitors from filing for approval with the same data set. This delay can postpone price competition and keep current prices stable for a few more years.

How will patients and insurers respond?
Insurers may negotiate rebates or encourage use of alternative therapies once generics enter, which can lower out‑of‑pocket costs for patients. Patients who rely on Kadcyla may face no change in price until a cheaper alternative gains approval and is commercially available.

What about regulatory hurdles for biosimilars?
Biosimilar approval requires demonstration of biosimilarity in preclinical and clinical studies, which takes time. Even after patent expiry, a biosimilar’s launch can be delayed by additional clinical testing, regulatory review, and manufacturing scale‑up.

Will the competition affect research and development?
The introduction of lower‑priced biosimilars often prompts original developers to invest in next‑generation conjugates or combination therapies, potentially leading to new patents that extend market control and influence pricing dynamics further down the line.

Sources
[1] DrugPatentWatch. Trastuzumab Emtansine (Kadcyla) patent and exclusivity details. https://www.drugpatentwatch.com/patents/TrastuzumabEmtansine.